FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)																	
1. Name and Address of Reporting Person * EMSTER KURT VON				Issuer Name and Ticker or Trading Symbol CymaBay Therapeutics, Inc. [CBAY]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
	ABAY T	(First) HERAPEU' , SUITE 13	TICS, INC., 7999		e of Ear 9/2017	rlies	t Transa	actio	n (M	Ionth/Day	y/Year)				(give title belo	w)		(specify be	ow)
(Street) NEWARK, CA 94560			4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							quire	red, Disposed of, or Beneficially Owned							
1.Title of S (Instr. 3)			2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)		tion	A. Securities Ad (A) or Disposed (Instr. 3, 4 and		ed of (D)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D)		Beneficial Ownership			
							Cod	e	V	Amoun	(A) o	r Prio	ce	,		or Ind (I) (Instr.		nstr. 4)	
Common	Stock		07/19/2017				P(1)		153,840	6 A	\$ 6.5	5 1,	753,84	6 ⁽²⁾		Ι	F	ee cotnotes) (4)
Common	Stock												90	0,000			D		
Common	Stock												17	7,236			I	K H E an E F E R T dd	y the onrad ans von mster III ad lizabeth von mster evocable rust ated anuary 3, 2005
Reminder: indirectly.	Report on a	separate line	for each class of sec	urities b	eneficia	ally (owned	i	Pers	sons wh	n this f	orm	are r	not req	ction of in uired to re I OMB cor	spond u	nless	SE	C 1474 (9- 02)
			Table II - I							isposed (Owned					
Security	Title of 2. 3. Transaction 3A. Deemed Execution Date (Month/Day/Year) any		tte, if Transaction Code Year) (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		A U S	4)	nt of lying	of Derivative Security (Instr. 5)		e C F Illy D S S c on(s) (I	Form of Derivativ Security: Direct (Dor Indirec				
					Code	V	(A)	(D)	Dat Exe	e rcisable	Expirat Date	ion T	Γitle 1	or Number of Shares					

Reporting Owners

Barretta Oraca Nama / Addams	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
EMSTER KURT VON C/O CYMABAY THERAPEUTICS, INC. 7999 GATEWAY BLVD, SUITE 130 NEWARK, CA 94560	X						

Signatures

/s/ John Heard, as attorney-in-fact	02/12/2018
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI, LP's ("ABV VI") July 19, 2017 purchase of 153,846 shares of common stock of CymaBay Therapeutics, Inc. ("Issuer") at a price of \$6.50 per share reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to
- (1) the extent of Reporting Person's pecuniary interest in the sales of common stock by ABV VI and Abingworth BioEquities Master Fund Limited ("ABE") made between September 28, 2017 and January 17, 2018. The Reporting Person has paid to Issuer \$692.00, representing the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar).
- (2) These shares were omitted from the Forms 4 filed by Reporting Person on October 2, 2017 and the twelve Form 4 filings made thereafter.
 - The shares purchased are held by ABV VI. Abingworth LLP ("Abingworth") is the investment manager of ABV VI and ABE (the "Abingworth Funds") and has been
- delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth.
 - From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of
- (4) Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.